The Fast-Forward trial demonstrates that a one-week radiotherapy schedule with five sessions is as effective as the traditional three-week course for early-stage breast cancer, with very low 10-year recurrence (3.6% for the 3-week course, 2.9% for the higher-dose 1-week schedule, and 2.1% for the lower-dose 1-week schedule).

Researchers describe the approach as safer, more effective, and more convenient, noting improved patient quality of life and reduced strain on the healthcare system.

Experts, including Murray Brunt and Judith Bliss from the Institute of Cancer Research, call the results definitive long-term evidence in favor of shorter radiotherapy schedules.

The healthcare impact could be transformative, with millions of patients benefiting from less treatment burden and better quality of life, while hospitals may see a lighter appointment load.

Karen Davis, a participant, shares her experience in the trial and remission, illustrating the psychosocial benefits and real-world relevance of shortened radiotherapy protocols.

Davis also discusses the personal and professional aftermath, including work in wigs for cancer patients and a willingness to advocate for shorter treatment.

Real-world experiences from participants highlight how shorter treatment can improve daily life and enable support for others with lived cancer experience.

The findings build on earlier five-year results and have already influenced clinical practice; since 2020, tens of thousands of UK patients have benefited from shorter radiotherapy under the NHS.

The study is sponsored by the Institute of Cancer Research (ICR) in London and was published in Lancet Oncology.

The trial, conducted by the ICR and Keele University and published in Lancet Oncology, extends the legacy of earlier results that shaped practice, with wide UK adoption since 2020.

Involving over 4,000 patients, the study confirms no increase in long-term side effects with the shorter, higher-dose schedule at the 10-year mark.